Advertisement

Endocrine

, Volume 28, Issue 2, pp 181–186 | Cite as

The metabolic effects of troglitazone in patients with diabetes and end-stage renal disease

  • Pharis Mohideen
  • Michael Bornemann
  • Jared Sugihara
  • Viola Genadio
  • Valerie Sugihara
  • Richard Arakaki
Original Articles

Abstract

Thiazolidinediones (TZD) are effective agents for the treatment of hyperglycemia, and appear ideal in diabetic patients with progressive or end-stage renal disease because of its predominant hepatic clearance. Troglitazone, the first available TZD for clinical use, was withdrawn due to safety concerns; however, studies completed with this agent can provide a better understanding of the class effect of TZDs. This study was an open-label, controlled clinical trial examining the safety and efficacy of troglitazone in type 2 diabetic patients with end-stage renal disease (ESRD). Twelve subjects were randomized to parallel study groups and treated for 6 mo with or without troglitazone at a maximum dose of 600 mg/d in addition to continuing their previous diabetes medications (insulin or sulfonylurea). The results showed no significant differences in glycemic control with or without troglitazone treatment for 6 mo. However, there was a significant reduction in insulin dosage with troglitazone treatment (22.9±7.3 units/d) than without troglitazone treatment (54±12.9 units/d) (p<0.05), as well as the change in the insulin dosage from baseline between the two groups (troglitazone, −8.4 units vs control, +4.3 units, p<0.05). Weight changes and aspartate aminotransferase levels greater than 1.5 times the upper limit of normal were not observed in participants of either treatment group. This study demonstrates that troglitazone was safe and effective for the treatment of hyperglycemia in patients requiring dialysis, and strongly supports the clinical use of currently available TZDs in diabetic patients with renal failure.

Key Words

End-stage renal disease thiazolidinediones reduced insulin dosage 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Nelson, R. G., Knowler, W. C., Pettitt, D. J., and Bennett, P. H. (1995). In: Diabetes in America. Harris, M. I. (ed.). NIH Publication No. 95-1468, pp. 349–400.Google Scholar
  2. 2.
    Defronzo, R. (1997). In: Ellenberg and Rifkin’s diabetes mellitus, 5th ed. Porte, D. and Sherwin, R. S. (eds.). Appleton and Lange: Stamford, CT, pp. 993–995.Google Scholar
  3. 3.
    Charpentier, G., Riveline, J. P., and Varroud-Vial, M. (2000). Diabetes Med. 26(S4), 73–85.Google Scholar
  4. 4.
    Viberti, G., Weseman, M. J., Pinto, J. R., and Messent, J. (1996). In: Joslin’s diabetes mellitus, 13th ed. Kahn, C. R. and Weir, G. C. (eds.). Lea and Febiger: Philadelphia, PA, pp. 721–722.Google Scholar
  5. 5.
    Morioka, T., Emoto, M., Tabata, T., et al. (2001). Diabetes Care 24(5), 909–913.PubMedCrossRefGoogle Scholar
  6. 6.
    Mak, R. H. K. (2000). Semin. Dialy. 13(1), 4–8.CrossRefGoogle Scholar
  7. 7.
    Heinrich, W. L. (ed.). (1994). Principles and practice of dialysis. Williams and Wilkins: Baltimore, MD, pp. 63–75, 89–97, and 111–129.Google Scholar
  8. 8.
    Saltiel, A. R. and Olefsky, J. M. (1996). Diabetes 45, 1661–1669.PubMedCrossRefGoogle Scholar
  9. 9.
    Vamecq, J. and Latruffe, N. (1999). Lancet 354, 141–148.PubMedCrossRefGoogle Scholar
  10. 10.
    Schoonjans, K. and Auwerx, J. (2000). Lancet 335, 1008–1010.CrossRefGoogle Scholar
  11. 11.
    Manley, H. J. and Allcock, N. M. (2003). Pharmacotherapy 23(7), 861–865.PubMedCrossRefGoogle Scholar
  12. 12.
    Chaplesky, M. C., Thompson-Culkin, K., Miller, A. K., Sack, M., Blum, R., and Freed, M. I. (2003). J. Clin. Pharmacol. 43(3), 252–259.CrossRefGoogle Scholar
  13. 13.
    Thompson-Culkin, K., Zussman, B., Miller, A. K., and Freed, M. I. (2002). J. Int. Med. Res. 30(4), 391–399.PubMedGoogle Scholar
  14. 14.
    Nelson, S. D. (2001). Adv. Exp. Med. Biol. 500, 33–43.PubMedCrossRefGoogle Scholar
  15. 15.
    Williams, M. E. and Roshon, B. (1999). Semin. Dialy. 12(1), 24–31.Google Scholar
  16. 16.
    Mak, R. H. K. (1994). Diabetes Rev. 2, 19–28.Google Scholar
  17. 17.
    Stefanovic, V., Nesic, V., and Stojimirovic, B. (2003). Int. J. Artif. Organs 26(2), 100–104.PubMedGoogle Scholar
  18. 18.
    Chan, N. N., Tong, P. C., So, W. Y., Leung, W. Y., Chiu, C. K., and Chan, J. C. (2004). Med. Sci. Monit. 10(3), PI44–48.PubMedGoogle Scholar
  19. 19.
    Agrawal, A., Sautter, M. C., and Jones, N. P. (2003). Clin. Ther. 25(11), 2754–2764.PubMedCrossRefGoogle Scholar
  20. 20.
    Goldstein, B. J. (2000). Int. J. Clin. Pract. 54(5), 333–337.PubMedGoogle Scholar
  21. 21.
    Gillies, P. S. and Dunn, C. J. (2000). Drugs 60(2), 333–343.PubMedCrossRefGoogle Scholar
  22. 22.
    Freidman, L. M., Furberg, C. D., and DeMets, D. L. (eds.). (1996). Fundamentals of clinical trials, 3rd ed. Mosby: St. Louis, MO, pp. 61–81.Google Scholar

Copyright information

© Humana Press Inc 2005

Authors and Affiliations

  • Pharis Mohideen
    • 1
  • Michael Bornemann
    • 1
  • Jared Sugihara
    • 1
  • Viola Genadio
    • 2
  • Valerie Sugihara
    • 1
  • Richard Arakaki
    • 1
  1. 1.Department of Medicine of the John A. Burns School of MedicineUniversity of Hawaii-ManoaUSA
  2. 2.Diabetes Center at Saint Francis Medical CenterHonolulu

Personalised recommendations